Fulcrum Therapeutics Inc. (FULC)
Fulcrum Therapeutics Statistics
Share Statistics
Fulcrum Therapeutics has 53.98M shares outstanding. The number of shares has increased by -13.15% in one year.
| Shares Outstanding | 53.98M |
| Shares Change (YoY) | -13.15% |
| Shares Change (QoQ) | 0.08% |
| Owned by Institutions (%) | 82.74% |
| Shares Floating | 47.85M |
| Failed to Deliver (FTD) Shares | 13.3K |
| FTD / Avg. Volume | 3.29% |
Short Selling Information
The latest short interest is 3.73M, so 6.92% of the outstanding shares have been sold short.
| Short Interest | 3.73M |
| Short % of Shares Out | 6.92% |
| Short % of Float | 8.96% |
| Short Ratio (days to cover) | 9.17 |
Valuation Ratios
The PE ratio is -28.12 and the forward PE ratio is null. Fulcrum Therapeutics's PEG ratio is 0.31.
| PE Ratio | -28.12 |
| Forward PE | n/a |
| PS Ratio | 3.42 |
| Forward PS | 2.2 |
| PB Ratio | 1.13 |
| P/FCF Ratio | -109.56 |
| PEG Ratio | 0.31 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Fulcrum Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.63, with a Debt / Equity ratio of 0.04.
| Current Ratio | 22.63 |
| Quick Ratio | 22.63 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.47 |
| Debt / FCF | -3.46 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.78M |
| Profits Per Employee | $-216.11K |
| Employee Count | 45 |
| Asset Turnover | 0.31 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -53.54% in the last 52 weeks. The beta is 2.12, so Fulcrum Therapeutics's price volatility has been higher than the market average.
| Beta | 2.12 |
| 52-Week Price Change | -53.54% |
| 50-Day Moving Average | 3.2 |
| 200-Day Moving Average | 4.81 |
| Relative Strength Index (RSI) | 58.85 |
| Average Volume (20 Days) | 404.06K |
Income Statement
In the last 12 months, Fulcrum Therapeutics had revenue of 80M and earned -9.72M in profits. Earnings per share was -0.17.
| Revenue | 80M |
| Gross Profit | 80M |
| Operating Income | -21.9M |
| Net Income | -9.72M |
| EBITDA | -18.24M |
| EBIT | -19.83M |
| Earnings Per Share (EPS) | -0.17 |
Balance Sheet
The company has 58.21M in cash and 8.63M in debt, giving a net cash position of 49.58M.
| Cash & Cash Equivalents | 58.21M |
| Total Debt | 8.63M |
| Net Cash | 49.58M |
| Retained Earnings | -519.4M |
| Total Assets | 260.72M |
| Working Capital | 238.88M |
Cash Flow
In the last 12 months, operating cash flow was -2.22M and capital expenditures -278K, giving a free cash flow of -2.5M.
| Operating Cash Flow | -2.22M |
| Capital Expenditures | -278K |
| Free Cash Flow | -2.5M |
| FCF Per Share | -0.04 |
Margins
Gross margin is 100%, with operating and profit margins of -27.37% and -12.16%.
| Gross Margin | 100% |
| Operating Margin | -27.37% |
| Pretax Margin | -12.16% |
| Profit Margin | -12.16% |
| EBITDA Margin | -22.8% |
| EBIT Margin | -27.37% |
| FCF Margin | -3.12% |
Dividends & Yields
FULC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for FULC is $4, which is 22% higher than the current price. The consensus rating is "Hold".
| Price Target | $4 |
| Price Target Difference | 22% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 3.6 |
| Piotroski F-Score | 4 |